Comparison · NCT01471444-57243f90
Arm A (Flu+Bu) vs Arm B (Flu+Clo+Bu): Number of Participants With Non Relapse Mortality at 100 Day Post Transplant
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (Flu+Bu) vs Arm B (Flu+Clo+Bu): Number of Participants With Non Relapse Mortality at 100 Day Post Transplant. Trial comparisons, record NCT01471444-57243f90. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01471444-57243f90
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0231 | 0.00788 | 0.0657 | wilson | |
| Risk in group 2 | 0.05 | 0.0231 | 0.105 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0269 | -0.0838 | 0.0234 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.462 | 0.118 | 1.8 | log | |
| Odds ratio, group 1 over group 2 | 0.449 | 0.11 | 1.84 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm A (Flu+Bu) than on Arm B (Flu+Clo+Bu) | 37.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (Flu+Bu) | Fludarabine 40 mg/m2 intravenous (IV) over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV for 60 years and younger or 4000 uMol-min IV for 61 years and older over 3 hours every 24 hours. Both delivered for 4 consecutive days (days -6 to -3). Stem cell transplant Day 0. | 3 | 130 | OG000 |
| Group 2 | Arm B (Flu+Clo+Bu) | Fludarabine 10 mg/m2 over 1 hour. Clofarabine 40 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, infused over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV for 60 years and younger or 4000 uMol-min IV for 61 years and older over 3 hours every 24 hours, immediately after Clofarabine. All delivered on 4 consecutive days (days -6 through -3). Stem cell transplant Day 0. | 6 | 120 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Non Relapse Mortality at 100 Day Post Transplant
- Description
- Number of participants expired from complications other than relapsed disease at 100 day Post Transplant.
- Time frame
- 100 day Post Transplant
- Population
Source ClinicalTrials.gov
Trial
- Title
- Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- NCT number
- NCT01471444
- Phases
- PHASE3
- Conditions
- Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
- Interventions
- Fludarabine, Clofarabine, Busulfan, Thymoglobulin, Stem Cell Infusion, Tacrolimus, Methotrexate
- Lead sponsor
- M.D. Anderson Cancer Center
- Results first posted
- 2021-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01471444?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01471444-57243f90